Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)
Үндсэн зохиолчид: | Bafadhel, M, Sing, D, Jenkins, C, Peterson, S, Bengtsson, T, Fageras, M |
---|---|
Формат: | Conference item |
Хэвлэсэн: |
European Respiratory Society
2018
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD
-н: Bafadhel, M, зэрэг
Хэвлэсэн: (2018) -
Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis
-н: Bafadhel, M, зэрэг
Хэвлэсэн: (2017) -
Investigating blood eosinophil count thresholds in patients with COPD
-н: Russell, R, зэрэг
Хэвлэсэн: (2018) -
Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
-н: Pavord, I, зэрэг
Хэвлэсэн: (2017) -
Case series of long-term macrolide therapy effect on eosinophil count in COPD
-н: Asciak, R, зэрэг
Хэвлэсэн: (2017)